Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
73.40
-0.05 (-0.06%)
Apr 3, 2025, 3:49 PM EDT - Market open
Insmed Revenue
In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth. Insmed had revenue of $104.44M in the quarter ending December 31, 2024, with 24.79% growth.
Revenue (ttm)
$363.71M
Revenue Growth
+19.17%
P/S Ratio
33.12
Revenue / Employee
$286,158
Employees
1,271
Market Cap
13.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
INSM News
- 7 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 9 days ago - Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference - PRNewsWire
- 24 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga
- 5 weeks ago - Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis - PRNewsWire
- 6 weeks ago - Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Insmed To Present at March 2025 Investor Conferences - PRNewsWire